Find Clinical Trials

Pembrolizumab in Treating Patients with Triple-Negative Breast Cancer

Principal Investigator: Danielle Bertoni, MD

Aspirin in Preventing Recurrence of Cancer in Patients with Node Positive HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy

Principal Investigator: Danielle Bertoni, MD

Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery

Principal Investigator: Norman Yeh, MD

Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer (TAILOR RT)

Principal Investigator: Norman Yeh, MD

Pacific Northwest Breast Cancer Screening Research

Principal Investigator: Jessica Germino, MD 

Genetic Testing in Screening Patients with Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Principal Investigator: John Strother, MD

Crizotinib in Treating Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

Principal Investigator: John Strother, MD

Erlotinib Hydrochloride in Treating Patients with Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

Principal Investigator: John Strother, MD

Maintenance Chemotherapy With or Without Stereotactic Body Radiation Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

Principal Investigator: Norman Yeh, MD

Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations

Principal Investigator: John Strother, MD

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO

Principal Investigator: John Strother, MD

Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

Principal Investigator: John Strother, MD

Principal Investigator: John Strother, MD

Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer

Principal Investigator: John Strother, MD

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients with Stage III-IVB Head and Neck Cancer Who Cannot Take Cisplatin

Principal Investigator: John Strother, MD

Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

Principal Investigator: John Strother, MD

Opening the Conversation: A study for reproductive-aged cancer survivors and their partners

Principal Investigator: Jessica Germino, MD 

A Phase 3, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low-dose Dexamethasone (pom/dex) in Participants with Relapsed/ Refractory Multiple Myeloma (RRMM) (DREAMM3)

Principal Investigator: John Strother, MD

Multi-Centre, Multi-National, Open Label, Safety Study of Etripamil Nasal Spray for Patients with Paroxysmal Supraventricular Tachycardia

Principal Investigator: Jeff Hsing, MD

Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID-19 Registry (COVID-19)

Principal Investigator: Brian Delmonaco, MD

A Phase 2b/3, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of Leronlimab for Patients with Severe or Critical Coronavirus Disease 2019 (COVID-19)

Principal Investigator: Brian Delmonaco, MD

ASCO Survey on COVID-19 in Oncology (ASCO) Registry

Principal Investigator: Nicholas Tedesco, DO

Exercise and Insulin Signaling in Human Skeletal Muscle

Samaritan Health Services Principal Investigators: Craig Graham, MD, Nicholas Phillips, MD, and Josh Lenhof, DO

Oregon State University Principal Investigators: Sean Newsom, PhD, and Matthew Robinson, PhD